Does CVS Caremark Cover Mounjaro?2026 Coverage, Prior Authorization & Cost
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
Coverage rules and medical facts come from CVS Caremark's own documents, FDA and Lilly prescribing information, and CMS — not from any provider that pays us.The 30-Second Answer
If you're asking does CVS Caremark cover Mounjaro, the short answer is yes for many members with documented type 2 diabetes — but coverage is never automatic. Your specific plan, formulary, diagnosis code, medication history, and prior authorization (PA) rules decide the result. Mounjaro is FDA-approved for type 2 diabetes only, not weight loss. With approved coverage and the Lilly Mounjaro Savings Card, eligible commercially insured patients can pay as little as $25 a month.
Match Your Caremark Result to the Right Next Step
Pull up your CVS Caremark portal at Caremark.com and search “Mounjaro” in the Check Drug Cost & Coverage tool. What you see there decides what to do next.
| What your Caremark portal says | What it usually means | What to do next |
|---|---|---|
| Covered, no PA flag | Your plan covers Mounjaro at this dose with no extra approval needed | Confirm your copay, activate the savings card, fill at your pharmacy |
| Prior authorization required | Your doctor must prove you meet your plan's clinical rules | Use the PA evidence checklist further down before they submit |
| Not covered / non-formulary | Your plan excludes Mounjaro or has it off-formulary | A formulary exception may still work — see the denial section |
| Quantity limit | Coverage exists, but the dose or fill size is capped | Match your prescription to the plan's exact limit |
| Step therapy required | You have to try a cheaper drug first | Document any prior trials of metformin, Ozempic, or other GLP-1s |
| Excluded for your use | Off-label (usually weight loss) requests get blocked here | Ask about Wegovy, Zepbound, or Foundayo coverage instead |
CVS Caremark Mounjaro Coverage Decoder
Answer five quick questions and we'll point you at the right next step — PA packet, appeal, formulary exception, or a different on-label GLP-1 path.
CVS Caremark Mounjaro Coverage Decoder
Step 1 of 5 · Answer all five to get your next step
What type of insurance do you have?
This tool translates your situation into a next step. It is not a guarantee of coverage and is not medical advice.
This tool is a translator that turns “it depends” into a clear next step. It is not a guarantee of coverage.
Why There's No One Answer to “Does CVS Caremark Cover Mounjaro?”
CVS Caremark is a pharmacy benefit manager (PBM) — the company that processes prescription claims — not the insurance plan itself. Your employer or plan sponsor (or the federal government, for FEP plans) picks the rules. CVS Caremark just enforces them. That's why your coworker's Caremark plan might cover Mounjaro at a $25 copay while yours requires three months of paperwork.
CVS Caremark publicly names three template commercial formularies its clients can pick from: Standard Control, Advanced Control, and Value. Tier placement, prior authorization rules, step therapy, and quantity limits change based on which template your employer chose and what plan-specific rules they layered on top.
CVS Caremark has also publicly stated that about one-third of employer-sponsored covered lives in its book don't have coverage for weight-loss medications at all. That's a different question from Mounjaro for type 2 diabetes — but it matters for any reader thinking about off-label use.
The July 2025 Formulary Change Did Not Touch Mounjaro
You may have read about CVS Caremark dropping a major GLP-1 from its formulary in July 2025. That was Zepbound (tirzepatide for weight loss) — not Mounjaro. CVS Caremark made Wegovy the preferred weight-loss GLP-1 instead. Mounjaro coverage for type 2 diabetes was explicitly unchanged. A preliminary Truveta analysis presented at AMCP 2026 confirmed the change applied only to the obesity indication.
If you've been on Mounjaro for diabetes, that change didn't affect you. If you've been on Mounjaro off-label for weight loss, it didn't directly change your coverage either — but it does mean Wegovy is now your plan's preferred weight-loss GLP-1, which can affect any future weight-loss appeal.
What's New in 2026
Two things worth knowing this year:
- Eli Lilly dropped CVS as the PBM for its own employees in November 2025, after CVS preferred Wegovy over Zepbound on its formulary. That news doesn't change your CVS Caremark coverage as a member — but it shows how fast these formulary fights move.
- The Medicare GLP-1 Bridge — a temporary federal program — starts July 1, 2026 and runs through December 31, 2027. Mounjaro is not on the Bridge's eligible weight-management list. Only Foundayo, Wegovy, and Zepbound KwikPen made the list.
Is Mounjaro Covered Automatically If I Have Type 2 Diabetes?
No. A documented type 2 diabetes diagnosis gives Mounjaro its cleanest CVS Caremark path, but it does not guarantee automatic coverage. Some claims pass through Caremark's diagnosis screen-out logic and pay at the pharmacy without prior authorization. Others reject and require a full PA, quantity-limit review, or plan-specific documentation. Whether yours pays clean or kicks out depends on what diagnosis codes are attached to the prescription, your medication history on file with Caremark, the dose requested, and your specific employer's plan design.
The good news: even when Caremark wants a PA, the path is well-defined. The next sections walk you through exactly what your prescriber needs.
How to Check Your Specific Caremark Mounjaro Coverage in 5 Minutes
Forget Googling generic blogs — your real answer lives in your own Caremark account. CVS Caremark tells members to use the Check Drug Cost & Coverage tool to see whether a medicine is covered, what the copay is, and whether a preferred alternative is available.
Here's the path most readers miss:
- Log in at Caremark.com (the actual member portal — not a search result).
- Open “Check Drug Cost & Coverage” from the menu.
- Search “Mounjaro”.
- Choose your dose (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg).
- Compare retail vs. mail-order pricing if both appear.
- Screenshot everything: the copay estimate, any PA / step therapy / quantity limit flags, and any “alternative medications” your plan suggests.
- Repeat the same search for Zepbound. The comparison tells you a lot — if Zepbound is excluded but Mounjaro is covered, your plan strongly prefers the diabetes path.
The 6 Questions to Ask Caremark Customer Service
If the portal isn't clear or your dose isn't listed, call the number on your Caremark card and ask these in order:
- Is Mounjaro on my plan's formulary for type 2 diabetes? What tier?
- Is prior authorization required? What are the specific PA criteria for my plan?
- Is there a step therapy requirement? Which medications do I have to try first?
- Are there quantity limits — how many pens per fill?
- After PA approval, what's my copay or coinsurance?
- If I'm denied, what's the appeal process and timeline?
What CVS Caremark's Prior Authorization Actually Requires
CVS Caremark publishes more than one antidiabetic GLP-1 / GIP-GLP-1 criteria document, and which one applies depends on your plan. The PA forms page currently links 5694-D, a “PA with Logic” document that can pay some claims at the pharmacy when a type 2 diabetes diagnosis or diabetes medication history is on file. The 5496-C “PA with Limit” document adds initial and continuation criteria plus the Mounjaro quantity limits. FEP members (Federal Employee Program) follow separate FEP-specific Mounjaro criteria available at info.caremark.com/dig/fep-pa.
The CVS Caremark Mounjaro PA Evidence Checklist
| What Caremark's PA criteria look for | What it means in plain English | What your prescriber needs in your file |
|---|---|---|
| Type 2 diabetes diagnosis | Confirmed T2D — not prediabetes, not weight management | ICD-10 code (E11.x) and date of diagnosis |
| A1c ≥ 6.5% (any documented value) | One of the FDA-recognized diagnostic markers | Lab result, even from years ago — original diagnostic value matters |
| Fasting plasma glucose ≥ 126 mg/dL after an 8-hour fast | Another accepted diagnostic marker | Lab result with timing noted |
| 2-hour plasma glucose ≥ 200 mg/dL during an OGTT | Another accepted marker | Lab result from OGTT, if performed |
| Random plasma glucose ≥ 200 mg/dL with hyperglycemia symptoms | Another accepted marker | Lab plus chart note describing symptoms |
| Prior medication trials | What you've tried before Mounjaro | List of drugs, doses, durations, outcomes (or contraindication notes) |
| No dual GLP-1 therapy | Confirms you're not on another GLP-1 at the same time | Current medication list |
| Current Mounjaro dose | What's being requested | Dose, frequency, fill quantity |
Source: CVS Caremark Antidiabetic GLP-1, GIP-GLP-1 Agonist criteria documents (5694-D and 5496-C). Verified May 2026.
You only need one of the four lab markers (A1c, FPG, OGTT, or random glucose with symptoms) to satisfy the diagnostic requirement. Most patients have an A1c value somewhere in their chart from years ago — that's usually the easiest to pull.
How Long PA Decisions Take
Don't trust a single timeline number — plans differ. For FEP, CVS Caremark says electronic prior authorization (ePA) can return a decision in minutes to hours, while fax or phone submissions can take 16 hours to 3 days. Employer commercial plans use different review windows. Your denial letter or plan document will state the exact timeline that applies to you.
The Renewal Trap That Catches People Off Guard
Here's a problem most readers don't see coming until they hit it: if Mounjaro worked and your A1c is now normal, your prescriber might submit only your current labs at renewal. Caremark's reviewer sees a healthy A1c and concludes there's no diabetes diagnosis to support coverage. Denial.
The fix: at renewal, your packet must show the original diagnostic labs from before treatment plus the response on Mounjaro. That's how the PA reviewer sees both the diagnosis and the proof that the drug is working.
If you've been denied at renewal after years on Mounjaro, this is almost always why.
👉 Pull our free GLP-1 Medical Necessity Letter Checklist →
A clean first PA submission beats five appeals. Use the same six-point template our editors use to review reader denials.
Mounjaro Quantity Limits on CVS Caremark
| Form | Limit (standard plans) | FEP limit | Duration of approval |
|---|---|---|---|
| Single-dose pens or vials | 4 per 21 days / 12 per 63 days | 12 units per 84 days | 12 months |
| KwikPen / multi-dose vial | 1 per 21 days / 3 per 63 days | 12 units per 84 days | 12 months |
Source: CVS Caremark 5496-C Antidiabetic GLP-1, GIP-GLP-1 Agonist PA-with-Limit document. Verified May 2026.
If your portal shows “quantity limit,” coverage exists — the dose or fill size doesn't match the plan's allowed amount. The fix: have your prescriber rewrite the script to match the limit, or request a quantity-limit exception if the prescribed dose is medically necessary.
Mounjaro Safety: What You Need to Know Before Filling Any Prescription
Boxed Warning
Mounjaro has a boxed warning — the FDA's strongest warning — for risk of thyroid C-cell tumors. Do not use Mounjaro if you or anyone in your family has had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Other serious risks listed in the FDA prescribing information include:
- Pancreatitis (inflammation of the pancreas)
- Hypoglycemia (low blood sugar) when used with insulin or sulfonylureas
- Serious allergic reactions
- Kidney problems from severe dehydration after vomiting or diarrhea
- Severe stomach problems including stomach paralysis (gastroparesis)
- Gallbladder problems including gallstones
- Aspiration risk during anesthesia or deep sedation
Tell your prescriber about all medications you take, especially insulin or sulfonylureas, and let your surgical or anesthesia team know you're on Mounjaro before any procedure. Read the full prescribing information at pi.lilly.com and ask your prescriber any questions.
What You'll Actually Pay for Mounjaro With CVS Caremark
The honest answer is anywhere from $25 to about $1,112 a month, depending on your coverage and which savings program you qualify for. No one pays the same price. Below is every realistic scenario, with verified dollar amounts from primary sources.
The Mounjaro Cost Matrix (Verified May 2026)
| Your situation | What you'll likely pay | What's happening |
|---|---|---|
| Covered for T2D + commercial insurance + Mounjaro Savings Card | As little as $25 for a 1-month or up to a 3-month fill | Best case: insurance pays most, savings card covers the rest, capped at $150 per 1-month fill |
| Covered for T2D + commercial, no savings card | Your Caremark portal copay or coinsurance | Deductible, tier, pharmacy type, fill length, and plan design decide the amount |
| Covered for T2D + Medicare Part D | Plan copay, capped at $2,100/year out-of-pocket on covered drugs in 2026 | Federal cap applies to plan-covered drugs only |
| PA denied / no T2D diagnosis | No covered Mounjaro path from the sources verified here | Check the portal for plan-listed alternatives; for weight management, see whether your plan covers an on-label AOM |
| Commercial drug insurance does NOT cover Mounjaro + eligible FDA-label use + Lilly single-dose pen Savings Card | As low as $499 for a 1-month fill | Max savings $647/fill, max annual savings $8,411, up to 13 fills per calendar year |
| No insurance, GoodRx coupon | About $1,097–$1,161/month | Roughly 14–19% off the ~$1,347 retail GoodRx average |
| List price (no help) | $1,112.16 per fill | Eli Lilly's current list price (4 pens / 28-day supply) |
Sources: mounjaro.lilly.com/savings-resources, startlilly.com/mounjaro/resources-for-saving, pricinginfo.lilly.com, GoodRx, CMS 2026 Part D guidance. Verified May 7, 2026. Lilly terms can change.
How the Mounjaro Savings Card Works With Your Caremark Plan
The Lilly Mounjaro Savings Card is the single biggest cost reducer for most readers. At the pharmacy counter, your CVS Caremark coverage processes first; the savings card processes as a secondary payer and covers the rest, up to its cap.
The fine print that matters
- For commercially insured patients with coverage: as little as $25 for a 1-month or up to a 3-month fill for an FDA-approved indication.
- Maximum monthly savings (covered): $150 per 1-month fill, $300 per 2-month fill, $450 per 3-month fill.
- Maximum annual savings (covered): $1,950 per calendar year.
- For commercially insured patients without Mounjaro coverage: as low as $499 for a 1-month fill, max savings $647/fill, max annual $8,411.
- Up to 13 fills per calendar year.
- Card expires December 31, 2026. Lilly has historically renewed annually but reserves the right to change terms.
- Government insurance is excluded. Medicare, Medicaid, TRICARE, VA, or any state pharmaceutical assistance program cannot use the savings card.
👉 Activate the Mounjaro Savings Card at mounjaro.lilly.com →
For eligible commercially insured patients using Mounjaro consistent with FDA-approved labeling. Government insurance is excluded. Lilly terms can change without notice.
What If You Can't Afford Mounjaro and Don't Qualify for the Savings Card?
Be careful with patient-assistance information online — a lot of it is outdated. As of this verification, Mounjaro is not listed on the Lilly Cares Foundation available-medications page. Lilly Cares directs patients whose medication isn't listed to the Medicine Assistance Tool (medicineassistancetool.org) to look for other resources. If you're on Medicare and need help affording Mounjaro, ask your prescriber about lower-cost diabetes medications your plan does cover.
Does CVS Caremark Cover Mounjaro for Weight Loss?
On most CVS Caremark plans, no — Mounjaro is rarely covered for weight loss alone. Mounjaro is FDA-approved for type 2 diabetes only. The FDA-approved tirzepatide brand for chronic weight management is Zepbound. CVS Caremark plans built their formularies around that distinction. Without a documented type 2 diabetes diagnosis, a Mounjaro request usually gets denied — and pushing the same paperwork repeatedly rarely changes the outcome.
The damaging admission you need to hear
If your only goal is weight loss and you don't have type 2 diabetes, you are likely on the wrong page — and that's a good thing, because it means we can save you weeks of denied PAs and frustration. CVS Caremark's preferred weight-loss GLP-1 since July 2025 is Wegovy (semaglutide). If your plan covers anti-obesity medications, Wegovy is your cleanest path. If you've already tried Wegovy without enough weight loss or couldn't tolerate it, the next move is a formulary exception for Zepbound — same medication as Mounjaro, but the FDA-approved weight-loss version. That's a real path that wins.
Trying to push Mounjaro through your plan for weight loss when Zepbound and Wegovy are right there is like trying to register a sports car as a delivery truck. The paperwork might technically work occasionally, but it almost never beats just driving the right vehicle.
The Cleaner Path for Weight-Loss Seekers
CVS Caremark has stated that about one-third of employer-sponsored covered lives in its book don't have weight-loss medication coverage at all. That matters for what to do next.
| Your situation | The path most likely to actually work |
|---|---|
| No T2D, plan covers Wegovy | Wegovy PA — BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition. Your plan can add its own rules. |
| No T2D, tried Wegovy without success | Zepbound formulary exception with documented Wegovy failure. |
| No T2D, plan excludes all weight-loss drugs | Cash-pay through Ro (Zepbound or Foundayo) or another telehealth provider. |
| No T2D, on Medicare | Medicare GLP-1 Bridge starting July 1, 2026 (Foundayo, Wegovy, or Zepbound KwikPen — Mounjaro is not on the list). |
👉 If you don't have type 2 diabetes, take our free 60-second GLP-1 matching quiz instead →
Three questions, no signup. We'll point you at the FDA-approved on-label path most likely to work with your insurance.
Mounjaro vs. Zepbound: Why CVS Caremark Treats Them Differently
Mounjaro and Zepbound contain the exact same medication — tirzepatide — made by the same company at the same doses. The difference is what the FDA approved each one for. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and (as of 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity. CVS Caremark treats them as separate drugs because the FDA does.
| Drug | Active ingredient | FDA-approved use | CVS Caremark coverage angle |
|---|---|---|---|
| Mounjaro | Tirzepatide | Type 2 diabetes (adults + kids 10+) | Covered on most plans for T2D with PA; almost never for weight loss |
| Zepbound | Tirzepatide | Chronic weight management; obstructive sleep apnea in adults with obesity | Removed from Standard Control, Advanced Control, and Value template formularies July 1, 2025; some employer plans still cover it |
| Wegovy | Semaglutide | Chronic weight management; cardiovascular risk reduction | CVS Caremark's preferred weight-loss GLP-1 since July 1, 2025 |
If you've been on Zepbound and your CVS Caremark plan stopped covering it, that's the July 2025 change. The plan is steering you to Wegovy. You can request a Zepbound formulary exception with documented Wegovy failure — but expect resistance. We've covered the full process in How to Switch From Mounjaro to Zepbound.
If CVS Caremark Denied Your Mounjaro: A Decision Tree
Don't appeal until you've read the denial letter. A Mounjaro denial can mean six different things, and the right response depends on which one. The denial letter — or a phone call to CVS Caremark — will tell you the exact reason.
Denial Reason → Right Move
| What the denial says | What it actually means | Your best move |
|---|---|---|
| Missing documentation | The criteria are met, but the proof wasn't attached | Resubmit with labs and chart notes. The easiest fix. |
| No type 2 diabetes diagnosis on file | Caremark didn't see the diagnostic evidence | Pull historical A1c, FPG, OGTT, or random glucose with symptoms — even from years ago |
| Current A1c is normal — diagnosis not supported | The classic renewal trap | Submit original diagnostic labs plus response-to-therapy notes |
| Step therapy required | You haven't tried the plan's preferred drug first | Document any prior trial of metformin, Ozempic, Trulicity, or Rybelsus — even partial trials count |
| Quantity limit exceeded | The dose or fill size is over the plan cap | Adjust the script or request a quantity-limit exception |
| Non-formulary / not covered | Your plan doesn't list Mounjaro at all | Request a formulary exception with medical necessity documentation |
| Not covered for this use (weight loss) | Plan excludes off-label Mounjaro | Switch the conversation to Wegovy, Zepbound, or Foundayo |
| Benefit exclusion | The plan excludes this entire drug category | Appeals are weak here — explore alternative providers or cash-pay |
When Appeals Are Worth It
Appeals work when the denial is fixable: missing labs, the wrong diagnosis code, missing continuation history, step-therapy documentation that wasn't attached, or a quantity-limit mismatch. Strong appeals add evidence — a Letter of Medical Necessity, prior trial documentation, and (when your plan allows it) a peer-to-peer call between your doctor and the Caremark medical reviewer. Appeals are much weaker when the denial is a true benefit exclusion.
The Phone Script for an Appeal
Call CVS Caremark and ask, exactly:
“Please send me the exact denial reason in writing, the clinical criteria you used, my appeal deadline, whether this is a formulary exclusion or a prior authorization denial, and whether a formulary exception or quantity-limit exception is available for my situation.”
👉 Pull the GLP-1 Medical Necessity Letter Checklist before your doctor writes anything →
A letter only works when the denial is fixable. Match the letter to the denial type or skip it.
CVS Caremark Through FEP, GEHA, Aetna, Medicare, or an Employer Plan
“I have CVS Caremark” isn't enough information to predict your Mounjaro outcome. FEP (Federal Employee Program), GEHA, Aetna, Medicare Part D, Medicare Advantage, union plans, and employer commercial plans all use CVS Caremark to administer prescriptions — but each one sets its own formulary, PA criteria, and appeal process.
FEP / BCBS Federal Employee Program
FEP uses its own Mounjaro prior approval criteria and form. The FEP Mounjaro form requires:
- Documented type 2 diabetes
- One qualifying lab marker (A1c ≥ 6.5%, FPG ≥ 126 mg/dL, OGTT ≥ 200, or random ≥ 200 with symptoms)
- Confirmation of no dual GLP-1 therapy (you cannot be on another GLP-1 at the same time)
- A 12-unit per 84-day quantity limit
- 12-month duration of approval
If you're a federal employee, the FEP form is the document to give your prescriber. It's available at info.caremark.com/dig/fep-pa. (See also: Does FEHB Cover Zepbound? for the weight-loss side of FEP.)
GEHA
GEHA plans run on CVS Caremark for pharmacy benefits and have their own GLP-1 coverage details. We've covered GEHA-specific GLP-1 paths in our GLP-1 Providers That Accept GEHA guide.
Aetna CVS Health
Many Aetna prescription benefits are administered through CVS Caremark, but the controlling rules are your Aetna plan documents, your Caremark portal result, and the denial letter. Use the same coverage-check framework above, then follow the appeal address, deadline, and form named in your specific plan documents. Don't assume Aetna and standard CVS Caremark commercial plans handle appeals identically.
Medicare Part D and Medicare Advantage
Medicare Part D and Medicare Advantage plans may cover Mounjaro for type 2 diabetes when it's on the plan formulary and the plan's criteria are met. Federal law still excludes drugs prescribed solely for weight loss from Part D coverage, so Mounjaro for off-label weight loss is not covered under Medicare. The 2026 Part D out-of-pocket cap of $2,100/year applies only to drugs your plan covers.
You cannot use the Mounjaro Savings Card if you have any government insurance — Medicare, Medicaid, TRICARE, VA, or any state pharmaceutical assistance program.
The Medicare GLP-1 Bridge (July 2026 – December 2027)
CMS announced a temporary Medicare program — the Medicare GLP-1 Bridge — running from July 1, 2026 through December 31, 2027. It gives some Medicare beneficiaries access to specific GLP-1s for chronic weight management.
Mounjaro is NOT on the Bridge's eligible weight-management list. The eligible drugs are Foundayo (orforglipron), Wegovy, and Zepbound KwikPen only.
Employer Commercial Plans
Each employer using CVS Caremark picks its own formulary tier and choices. Some cover all FDA-approved anti-obesity medications. Some exclude every weight-loss drug. Most fall somewhere in between. The portal walkthrough above is the only reliable way to know yours.
👉 Get your personalized coverage map →
Tell us your insurance type and goal — we'll point you at the path most likely to work for your situation in under 60 seconds.
The Best Telehealth Path When CVS Caremark Coverage Gets Complicated
If your CVS Caremark coverage works and your existing doctor is on top of it, you don't need a new provider — keep your current setup. Most readers reach this section because something broke: a denial, a renewal that fell through, an off-label use that won't get approved, or a doctor's office that doesn't know how to handle GLP-1 PAs.
Path 1: You Have Type 2 Diabetes and Need a Provider Who Will Prescribe Mounjaro
Sesame Care
Their dedicated Mounjaro page is built for adults with type 2 diabetes who need a prescription visit. The provider can assist with prior authorization paperwork. Success by Sesame weight-management subscription starts at $59 per month with an annual subscription and includes telehealth visits, unlimited messaging, labs in most states, and ongoing clinical care.
- ✓ Actually prescribes Mounjaro (some big-name telehealth brands don't)
- ✓ Provider can assist with prior authorization paperwork to lower cost
- ✓ Costco members get an additional discount
- ✓ Same-day video visits available
- ✓ HSA/FSA eligible for visit fees and most prescriptions
Success by Sesame from $59/month with annual subscription · Confirm current Mounjaro-specific visit pricing on Sesame before booking · Sponsored
Path 2: You Were Denied Mounjaro for Weight Loss and Need Insurance Help With an On-Label Alternative
Ro Body
The strongest fit if your goal is weight loss, your CVS Caremark plan won't cover Mounjaro for that, and you want help navigating insurance toward an on-label drug. Ro does not currently offer Mounjaro itself — they carry Zepbound and Foundayo. What makes Ro the right call here is their GLP-1 Insurance Coverage Checker (free) and their insurance concierge that fights for coverage on FDA-approved GLP-1s and handles all prior authorization paperwork.
Get started for $39, then as low as $74/month with annual plan paid upfront.
- ✓ Free GLP-1 Insurance Coverage Checker — runs your benefits before you commit
- ✓ Insurance concierge submits PAs and fights denials on your behalf
- ✓ Carries Zepbound (FDA-approved for chronic weight management) and Foundayo
- ✓ Cash-pay pricing matches LillyDirect and NovoCare for FDA-approved branded GLP-1s
- ✓ Insurance concierge included with Ro Body membership
Free coverage report · Ro does not currently offer Mounjaro; covers Zepbound, Wegovy, Foundayo, and Ozempic · Sponsored
Both Routes Have Real Limits
Sesame is consultation-based — visit fees are separate from medication cost, and they don't bill insurance for the visit itself. Ro doesn't carry Mounjaro, so if your goal is specifically Mounjaro continuation for type 2 diabetes, Sesame is the better fit. If your goal is on-label weight management with insurance navigation help, Ro is. If you're not sure which fits, start with our quiz.
👉 Take our free 60-second GLP-1 matching quiz →
Three questions about your insurance, diagnosis, and goal.
A Quick Word on Compounded Tirzepatide
Compounded tirzepatide is not the same as Mounjaro and is not a CVS Caremark Mounjaro formulary benefit in the sources verified for this page. Compounded medications are made by specialized pharmacies under different rules than FDA-approved drugs. This page is about CVS Caremark coverage of Mounjaro — the FDA-approved drug. If you've decided to explore compounded options, that's a separate conversation with separate rules, separate risks, and a separate set of providers. We won't pretend they're interchangeable, because they're not.
Common Reader Scenarios
Names, employers, and specifics removed to protect privacy. These are the patterns we see most often when readers email us about CVS Caremark Mounjaro denials.
The renewal scenario
A reader has been on Mounjaro for three years for type 2 diabetes. Their A1c is now 5.8%. CVS Caremark wants the original diagnostic labs — from before treatment started — to renew the PA. The reader's doctor sends only current labs. The PA gets denied because, on paper, there's no diabetes anymore. The fix: pull the original A1c (or FPG, or OGTT) from years ago and resubmit with treatment-response notes.
The step therapy scenario
A reader is newly diagnosed with type 2 diabetes and their endocrinologist writes Mounjaro as first-line therapy. CVS Caremark denies the PA because their plan requires metformin first. The fix: document any contraindication to metformin (kidney function, GI intolerance, allergy) — or take three months on metformin first, document the response, and resubmit.
The off-label scenario
A reader without a type 2 diabetes diagnosis has their doctor write Mounjaro for weight loss. CVS Caremark denies it. The reader appeals with a Letter of Medical Necessity. CVS Caremark denies again because it's not an FDA-approved use under their criteria. The fix: switch the conversation to Wegovy (CVS Caremark's preferred weight-loss GLP-1), or to a Zepbound formulary exception if Wegovy didn't work.
The pattern across all three: the people who get covered fastest match their PA packet to the plan's exact criteria the first time. At renewal, the smart move is always to include original diagnostic labs alongside current results.
What We Actually Verified
This page was built from primary sources. Here's exactly what we checked and where.
| What we verified | Source | Last verified |
|---|---|---|
| CVS Caremark says coverage depends on plan and formulary | caremark.com/manage-prescriptions | May 7, 2026 |
| Caremark's Check Drug Cost & Coverage tool is the recommended verification path | caremark.com | May 7, 2026 |
| Antidiabetic GLP-1 PA-with-Logic document (5694-D) | info.caremark.com/dig/pa-forms | May 7, 2026 |
| Antidiabetic GLP-1 PA-with-Limit document (5496-C) — initial criteria, continuation, quantity limits | info.caremark.com/content/dam/.../5496-C_GLP-1-Agonist.pdf | May 7, 2026 |
| FEP Mounjaro criteria and form | info.caremark.com/dig/fep-pa | May 7, 2026 |
| July 2025 Zepbound formulary change (Standard, Advanced Control, Value) | business.caremark.com/.../glp-1s.html | May 7, 2026 |
| ~1/3 of employer-sponsored covered lives lack weight-loss drug coverage | business.caremark.com/.../glp-1s.html | May 7, 2026 |
| Truveta AMCP 2026 analysis (preliminary, not peer reviewed) | truveta.com/blog/research/amcp-2026-impact-cvs-glp-1-formulary-change | May 7, 2026 |
| Mounjaro FDA-approved indication (T2D, ages 10+) and boxed warning | pi.lilly.com/us/mounjaro-uspi.pdf and mounjaro.lilly.com | May 7, 2026 |
| Mounjaro list price $1,112.16 per fill | pricinginfo.lilly.com/mounjaro | May 7, 2026 |
| Savings Card terms — covered: as little as $25, max $150/fill, 13 fills, expires 12/31/2026 | mounjaro.lilly.com/savings-resources and startlilly.com | May 7, 2026 |
| Savings Card non-covered terms ($499/1-month, 13 fills, $8,411 annual max) | startlilly.com/mounjaro/resources-for-saving | May 7, 2026 |
| Government insurance excluded from savings card | mounjaro.lilly.com/savings-resources | May 7, 2026 |
| Mounjaro NOT listed on Lilly Cares available medications | lillycares.com/available-medications | May 7, 2026 |
| Medicare Part D 2026 out-of-pocket cap of $2,100 | medicare.gov/health-drug-plans/part-d/basics/costs | May 7, 2026 |
| Medicare GLP-1 Bridge eligible drugs (Foundayo, Wegovy, Zepbound KwikPen — Mounjaro absent) | cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge | May 7, 2026 |
| Ro does not currently offer Mounjaro; offers Zepbound and Foundayo | ro.co/weight-loss/mounjaro and ro.co/weight-loss | May 7, 2026 |
| Sesame Mounjaro page for type 2 diabetes prescription visits and PA assistance | sesamecare.com/medication/mounjaro | May 7, 2026 |
| Success by Sesame starts at $59/month with annual subscription | sesamecare.com/medication/mounjaro | May 7, 2026 |
What we couldn't verify without your specific plan login:
- Your exact copay or coinsurance percentage
- Your employer's plan-specific exclusions
- Whether your prior authorization is currently active
- Whether your local pharmacy stocks 90-day supplies
- Whether your diagnosis and labs meet your plan's internal review rules
· Next scheduled re-verification: August 7, 2026
Frequently Asked Questions
- Does CVS Caremark cover Mounjaro?
- CVS Caremark covers Mounjaro on many plans, but coverage is never automatic. It depends on your specific plan, formulary, diagnosis, dose, and quantity limits. The fastest way to verify is the Caremark Check Drug Cost & Coverage tool at caremark.com.
- Does CVS Caremark cover Mounjaro for weight loss?
- On most CVS Caremark plans, no. Mounjaro is FDA-approved only for type 2 diabetes — weight loss is off-label. CVS Caremark plans almost universally deny off-label Mounjaro requests and steer weight-loss patients to Wegovy (the preferred weight-loss GLP-1 since July 2025) or Zepbound through a formulary exception.
- Does Mounjaro require prior authorization with CVS Caremark?
- Most often, yes — though some claims with a clear T2D diagnosis pass through Caremark's screen-out logic without a full PA. CVS Caremark publishes the antidiabetic GLP-1 PA criteria that govern Mounjaro reviews (forms 5694-D and 5496-C), with type 2 diabetes documentation requirements and quantity limits.
- What lab evidence does CVS Caremark accept for Mounjaro PA?
- Any one of: A1c ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL after an 8-hour fast, 2-hour plasma glucose ≥ 200 mg/dL during an OGTT, or random plasma glucose ≥ 200 mg/dL with hyperglycemia symptoms.
- Did the July 2025 CVS Caremark formulary change affect Mounjaro?
- No. The July 2025 change removed Zepbound (tirzepatide for weight loss) from the Standard Control, Advanced Control, and Value template formularies in favor of Wegovy. Mounjaro coverage for type 2 diabetes was explicitly unchanged.
- What CVS Caremark tier is Mounjaro on?
- Tier placement depends on the specific plan formulary your employer or sponsor selected. Confirm via your Caremark portal — tier wording is shown next to the drug in the Check Drug Cost & Coverage tool.
- Can I use the Mounjaro Savings Card with CVS Caremark?
- Yes, if you have commercial insurance and the prescription is for an FDA-approved use. Eligible covered patients pay as little as $25/month (capped at $150 per 1-month fill, $1,950/year). Patients with Medicare, Medicaid, TRICARE, VA, or any state assistance program are not eligible.
- Why did CVS Caremark deny my Mounjaro PA?
- The most common reasons are: missing diagnostic documentation, no documented type 2 diabetes, current A1c normal at renewal without original labs, step therapy not yet completed, dose or quantity over plan limits, or off-label use for weight loss. The denial letter will state the exact reason.
- How long does CVS Caremark take to approve Mounjaro PA?
- It varies by plan and submission method. For FEP, electronic prior authorization can return a decision in minutes to hours, while fax or phone submissions can take 16 hours to 3 days. Employer commercial plans use different review windows — your denial letter or plan document states the exact timeline.
- What's the CVS Caremark quantity limit for Mounjaro?
- In CVS Caremark's 5496-C document, single-dose pens or vials are capped at 4 per 21 days or 12 per 63 days, with a 12-month duration of approval. KwikPen and multi-dose vial packaging is capped at 1 per 21 days or 3 per 63 days. FEP uses a separate limit of 12 units per 84 days.
- Can I get Mounjaro through CVS Caremark mail order?
- Yes, on most plans. Mail order often offers a 90-day supply at a lower copay than retail. Check your portal for the price difference.
- Is Aetna CVS Health different from CVS Caremark for Mounjaro?
- Many Aetna prescription benefits are administered through CVS Caremark, but the controlling rules are your Aetna plan documents and your portal result. Use the same coverage-check framework, then follow the appeal address and form named in your plan documents.
- Does Medicare Part D cover Mounjaro?
- Medicare Part D and Medicare Advantage prescription drug plans may cover Mounjaro for type 2 diabetes when it's on the plan formulary and the plan's criteria are met. Medicare does not cover Mounjaro for weight loss alone. The 2026 Part D out-of-pocket cap is $2,100/year on plan-covered drugs.
- Is Mounjaro on the Medicare GLP-1 Bridge?
- No. The Medicare GLP-1 Bridge (July 2026 – December 2027) only covers Foundayo, Wegovy, and Zepbound KwikPen for weight management. Mounjaro is not on the eligible Bridge list. Bridge access also requires the program's eligibility and PA criteria.
The Bottom Line
If you have CVS Caremark and documented type 2 diabetes, Mounjaro is a real coverage path — but your portal result still decides the tier, PA rule, quantity limit, and your actual cost. Some claims pass clean through Caremark's screen-out logic. Others kick out and need a PA built around the exact criteria your plan uses (forms 5694-D, 5496-C, or FEP). At renewal, always include original diagnostic labs alongside current results — that's the single most common point of failure.
If you're commercially insured and eligible for the Lilly Mounjaro Savings Card, your monthly cost can be as little as $25. If you have Medicare, Medicaid, TRICARE, VA, or any other government plan, that card isn't available — work with your prescriber on covered alternatives.
If you're seeking Mounjaro for weight loss without a T2D diagnosis, your plan will almost certainly say no. The better paths are Wegovy (CVS Caremark's preferred weight-loss GLP-1), Zepbound through a formulary exception, or — if you're on Medicare — Foundayo, Wegovy, or Zepbound KwikPen through the Medicare GLP-1 Bridge starting July 2026.
The single highest-leverage move you can make right now is the 5-minute Caremark portal check. Get your specific result, screenshot it, then come back to the matching row in the table at the top of this page. From there, the rest is just executing the right next step — PA packet, appeal, exception request, or pivot to a covered alternative.
Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.
Get your personalized GLP-1 path →